Adderall and a GLP-1: Taking an ADHD Stimulant With Ozempic or Zepbound

No FDA label lists an interaction between an ADHD stimulant and a GLP‑1. Adderall, Vyvanse and Concerta do not mention semaglutide or tirzepatide, and Ozempic, Wegovy, Mounjaro and Zepbound do not mention stimulants. No study has tested the pairing either. What the labels do show is overlap. Both kinds of drug raise heart rate, both cut appetite, and the GLP‑1 slows the stomach that a stimulant capsule has to pass through. None of that rules the combination out. It does mean the prescriber needs to know about both.

What each label says about the other drug: nothing

Ozempic and Wegovy^[5][6] never name amphetamine, lisdexamfetamine, methylphenidate or stimulants anywhere in their prescribing information, and neither do Zepbound and Mounjaro.^[7][8] Going the other way, Adderall and Adderall XR^[1][2] name no GLP‑1, no semaglutide or tirzepatide, and no diabetes medicine of any kind; Vyvanse and Concerta are silent too.^[3][4] So there is no listed interaction, and no warning against the combination on either side. That is different from phentermine, a close chemical relative of amphetamine, whose own label advises against pairing it with any other weight-loss drug; phentermine and a GLP-1 covers that case.

Silence on a label means the interaction was not studied or not found. It does not mean the two drugs were tested together and cleared. Each label still carries warnings that apply to the person taking both:

Heart rate: two drugs that each push the pulse up

The Adderall, Vyvanse and Concerta labels carry the same sentence: CNS stimulants raise blood pressure by about 2 to 4 mmHg and heart rate by about 3 to 6 beats a minute on average, “some patients may have larger increases”, and patients should be monitored for a fast heart rate and high blood pressure.^[1][3][4] In the adult Adderall XR trial, tachycardia was reported by 6% against 3% on placebo.^[2] In the Vyvanse binge-eating trials, an increased heart rate was reported by 7% against 1%.^[3]

GLP‑1s raise resting heart rate too. Wegovy’s label reports an average rise of 1 to 4 beats a minute against placebo, and a jump of 20 or more at some visit in 26% of people on the drug against 16% on placebo. Anyone whose heart races or pounds while sitting still is asked to tell their prescriber.^[6] Ozempic’s label reports 2 to 3 beats a minute,^[5] Zepbound’s 1 to 3,^[7] and Mounjaro’s 2 to 4 against 1 on placebo.^[8] Brand by brand, the full picture is in GLP-1 drugs, heart rate and palpitations.

Nobody knows whether the two effects simply add up. The labels give no reason to think they cancel out. The stimulant labels say to avoid the drugs in people with structural heart abnormalities, cardiomyopathy, serious arrhythmia or coronary artery disease, and note that sudden death has been reported in people with serious heart disease on normal ADHD doses.^[1] Those warnings do not change when a GLP‑1 is added.

Appetite: two drugs that each cut it

Every stimulant here lists a smaller appetite among its frequent complaints, and the trials put numbers on it:

On the GLP‑1 side, lower appetite is how the drug works, and nausea comes with it. On Wegovy, 44% of adults reported nausea against 16% on placebo, and 24% vomiting against 6%.^[6] On Zepbound, nausea ran 25% to 29% across doses against 8%.^[7]

Stack the two and the risk is simple: eating too little. A morning stimulant often wipes out lunch, and a GLP‑1 can shrink the evening meal that used to make up for it. Low intake on a GLP‑1 alone is already common; eating too little on a GLP-1 sets out how common, and the deficiencies that follow. Protein is usually the first thing to go; protein targets and the lab panel covers what to aim for. Planning meals by the clock rather than by hunger is the practical answer, because on both drugs, hunger stops being a reliable signal.

Two more overlaps are small but real. Dry mouth is one of the most frequent stimulant complaints (35% on Adderall XR, 36% on Vyvanse in the binge-eating trials),^[2][3] which matters when a GLP‑1 already makes it harder to drink enough. Constipation appears on both sides: 6% against 1% on Vyvanse,^[3] and as many as 24% against 11% on Wegovy.^[6] GLP-1 constipation: what works covers the options.

A slower stomach and the stimulant dose

Every GLP‑1 label warns that delayed gastric emptying could affect how oral medicines are absorbed. The Ozempic label adds that in its clinical pharmacology studies, semaglutide did not change absorption of the drugs tested to any clinically relevant degree.^[5] Wegovy’s says to monitor the effects of oral medicines taken alongside it.^[6] How that plays out for warfarin, the pill and thyroid medicine is in GLP-1 drugs and your other medications. The tirzepatide labels go further, asking for monitoring of oral drugs “dependent on threshold concentrations for efficacy”.^[7][8] Whether a stimulant counts is not stated. No label names one, and no stimulant has been tested with a GLP‑1.

The closest real data come from acetaminophen (Tylenol), measured in the tirzepatide studies. After a first 5 mg dose of tirzepatide, acetaminophen’s peak level fell by 55% and arrived an hour later. By week 6, on 15 mg, there was no meaningful effect, and total absorption over 24 hours was not affected.^[7] The slowing peaks with the very first injection and then wears off.

The stimulant labels supply a second clue: food, which also slows the stomach. A high-fat meal delays Adderall XR’s peak by about 2.5 hours but does not change how much amphetamine is absorbed.^[2] Food delays Vyvanse’s peak by about an hour, again without changing the total.^[3] Vyvanse is also a prodrug, switched on in the blood by red blood cells rather than in the gut.^[3] Adderall XR contains two kinds of beads, one released at once and one delayed.^[2]

Put together, a reasonable reading is that a GLP‑1 is more likely to change when a stimulant kicks in than how much of it gets absorbed, and most likely early on, or when the GLP‑1 dose steps up. That is an inference from neighboring data, not a measured result. In practice it means a morning dose that seems to start later or wear off at a different time in the first weeks of a GLP‑1 is worth mentioning before anyone changes the dose. Only a prescriber should change it.

Concerta has one specific caution. Its tablet keeps its shape all the way through the gut, and its label says it should not normally be given to people with severe narrowing of the digestive tract, citing rare reports of obstruction in people with known strictures.^[4] The GLP‑1 labels list ileus and intestinal obstruction among reports received after approval.^[5][6][7] We found no report linking the two. Severe constipation, swelling or pain on a GLP‑1 is a reason to call whoever prescribes the Concerta as well.

Antacids and heartburn

This is the overlap people are least likely to know about. Heartburn and indigestion are listed side effects of GLP‑1s: on Wegovy, dyspepsia affected 9% against 3% on placebo, and reflux 5% against 3%;^[6] Zepbound’s figures are similar.^[7] The obvious reach is an antacid. Yet the Adderall and Adderall XR labels say gastrointestinal alkalinizing agents, which raise amphetamine blood levels and its effect, should be avoided with the drug.^[1][2] The Vyvanse label names urinary alkalinizers such as sodium bicarbonate.^[3] Anyone on an amphetamine who starts needing heartburn treatment on a GLP‑1 should ask a pharmacist which product to use.

What the studies show: almost nothing on the pairing

We found no randomized trial, pharmacokinetic study or large cohort of an ADHD stimulant taken with semaglutide or tirzepatide. What exists touches the question from the side.

• One small clinic cohort. In a retrospective study of binge-eating disorder at an Oklahoma obesity clinic, 19 people took semaglutide alone, 13 took it with topiramate or lisdexamfetamine, and 16 took one of those drugs without semaglutide. Semaglutide alone cut binge-eating scores the most. Adding the other drug did not improve on it.^[9] The study table shows only two people in the combination group on Vyvanse, so it says almost nothing about lisdexamfetamine specifically. The lead author has received speaker fees from Novo Nordisk.
• Binge eating more broadly. A 2026 systematic review of GLP‑1 drugs for binge eating found 12 studies, mostly with fewer than 75 people. They consistently showed less binge eating, with no new psychiatric safety concerns.^[10] Vyvanse is approved for moderate to severe binge-eating disorder in adults.^[3] GLP-1 drugs and eating disorders covers that ground.
• Teenagers on liraglutide. In 966 Israeli adolescents dispensed liraglutide, only 18% kept filling it for seven months or more. Among those with ADHD, the ones being treated for it stayed on liraglutide more often.^[11] That is an association in pharmacy records, not evidence that either drug changed the other.
• A psychiatric chart review. Among 226 adults on GLP‑1s at one university hospital, a small number picked up a new ADHD diagnosis during treatment, at a mean of 7.8 months.^[12] A chart review cannot say whether the drug had anything to do with it.

The reason the question comes up so often is the overlap between the two conditions. A meta-analysis of 42 studies and more than 728,000 people found obesity in 28.2% of adults with ADHD against 16.4% of those without. People being treated with ADHD medication were not at higher risk.^[13]

A stimulant is not a weight-loss drug

Vyvanse’s label rules out using it to lose weight. It says other sympathomimetic drugs used that way have been tied to serious cardiovascular events, and that it has not been shown safe or effective for obesity.^[3] Amphetamine as an obesity treatment is being studied again: an Australian randomized trial is testing dexamphetamine against placebo for six months in primary care.^[14] Until results exist, a stimulant prescribed for ADHD is an ADHD treatment, and the GLP‑1 is the weight treatment. Raising a stimulant dose for appetite, or adding one for weight, is outside both labels.

Shortages and switching

FDA has listed immediate-release mixed amphetamine salts, the generic form of Adderall, as in shortage since October 2022. The entry was still marked current in October 2026. Lisdexamfetamine capsules and extended-release methylphenidate tablets were also listed as current shortages.^[15] Shortages push people from one brand, generic or release type to another. Changing a stimulant formulation in the same weeks as starting or raising a GLP‑1 makes it hard to tell which change caused a new side effect. If both have to happen, it helps to tell each prescriber about the other change.

What to ask a prescriber

1. Does the doctor prescribing the GLP‑1 know about the stimulant, and the reverse? They are often different clinicians, and neither drug’s label will prompt the question.
2. How will my heart rate and blood pressure be checked? Ask for a reading before the GLP‑1 starts and again after dose increases.
3. How should I plan meals? With both drugs cutting appetite, a set eating schedule and a protein target are more reliable than hunger.
4. What should I use for heartburn? The amphetamine labels warn against gastrointestinal alkalinizing agents; ask a pharmacist before reaching for an antacid.
5. What if my stimulant seems to work differently? Note when doses seem to start and wear off in the first weeks, and report it rather than adjusting the dose yourself.